Put otherwise, we hypothesise CD4-positive T-cells delivered BCR::ABL1 immunogenic peptides to invoke immunity, HTLV-1 was an adjuvant that boosted anti-CML immunity, and CD4-positive, BCR::ABL1-positive clones were self-limiting by acting as auto-vaccines [8]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.